Cytox Revenue and Competitors
Estimated Revenue & Valuation
- Cytox's estimated annual revenue is currently $930k per year.
- Cytox's estimated revenue per employee is $155,000
Employee Data
- Cytox has 6 Employees.
- Cytox grew their employee count by -40% last year.
Cytox's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | PA to CEO, Office Administrator | Reveal Email/Phone |
3 | Clinical Product Development Lead | Reveal Email/Phone |
Cytox Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Cytox?
Cytox is developing transformational prognostic technology that may contribute to the assessment of an individual's risk of developing dementias such as Alzheimer's disease. We are collaborating with academic researchers and the pharmaceutical industry to develop blood-based assays to aid in the development of new, more effective dementia treatments. We intend to play our part in the fight against Alzheimer's disease and other dementias. .
keywords:N/AN/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cytox News
2022-03-30 - New insights into the genetic etiology of Alzheimer's disease and ...
He served as a scientific advisory board member for Functional Neuromodulation, Axovant, Eisai, Eli Lilly and Company, Cytox, GE Healthcare,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 6 | N/A | N/A |
#2 | $0.9M | 6 | -14% | N/A |
#3 | $0.4M | 6 | -14% | N/A |
#4 | $0.4M | 6 | -50% | N/A |
#5 | $0.5M | 7 | -22% | N/A |